# Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors

> **NCT02390843** · PHASE1 · COMPLETED · sponsor: **Emory University** · enrollment: 13 (actual)

## Conditions studied

- Retinoblastoma
- Clear Cell Sarcoma
- Renal Cell Carcinoma
- Rhabdoid Tumor
- Wilms Tumor
- Hepatoblastoma
- Neuroblastoma
- Germ Cell Tumors
- Ewings Sarcoma
- Non-rhabdomyosarcoma Soft Tissue Sarcoma
- Osteosarcoma
- Rhabdomyosarcoma

## Interventions

- **DRUG:** Simvastatin
- **DRUG:** Cyclophosphamide
- **DRUG:** Topotecan
- **DRUG:** Myeloid growth factor

## Key facts

- **NCT ID:** NCT02390843
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2019-09-22
- **Final completion:** 2019-09-22
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2020-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02390843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02390843, "Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02390843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*